Tim Eisen

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Bernard Escudier, Tim Eisen, Camillo Porta et al. · Annals of Oncology · 2012 · 275 citations · Full text

Medicine, Nephrology, Oncology +14

Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial.

Robert J. Motzer, Dmitry Nosov, Tim Eisen et al. · Journal of Clinical Oncology · 2012 · 95 citations

Medicine, Oncology, Pharmacology +17

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer

Dana W.Y. Tsui, Muhammed Murtaza, Alvin Wong et al. · EMBO Molecular Medicine · 2018 · 93 citations · Full text

Medicine, Molecular Biology, Oncology +13

The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort

Tobias Klatte, Kevin Gallagher, Luca Afferi et al. · BMC Medicine · 2019 · 54 citations · Full text

Medicine, Oncology, Surgery +17

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

Ana M. Molina, Thomas E. Hutson, Dmitry Nosov et al. · European Journal of Cancer · 2018 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14